Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SMC Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

NCT00333515
View directory record Official record
Conditions
Healthy Volunteers, Chemical Terrorism, Chemical Warfare
Interventions
Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers

NCT04265456
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin 100mg, Acetaminophen 1300mg
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

NCT06585488
View directory record Official record
Conditions
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
Interventions
BGB-53038, Tislelizumab, Cetuximab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

NCT03954106
View directory record Official record
Conditions
DLBCL, Neurotoxicity Syndromes
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional

At-risk Intervention and Mentoring Evaluation

NCT02174224
View directory record Official record
Conditions
Violence
Interventions
Brief Intervention, Case Management, Standard Medical Care
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
14 Years to 24 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Active, not recruiting Not applicable Interventional

Healthy Opioid Prescription Engagement

NCT05141266
View directory record Official record
Conditions
Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Interventions
Patient Navigation, Standard Medication Counseling (SMC)
Behavioral · Other
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT07287397
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

NCT00548691
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Phase 1 Interventional

CARv3-TEAM-E T Cells in Glioblastoma

NCT05660369
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Interventions
CARv3-TEAM-E T cells
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 4 Interventional Results available

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

NCT01938547
View directory record Official record
Conditions
Pediatric Perioperative Blood Pressure Management
Interventions
clevidipine
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Stanford, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Pharmacists and Opioid Misuse

NCT03149718
View directory record Official record
Conditions
Opioid Misuse
Interventions
Brief Intervention Medication Therapy Management, Standard Medication Counseling (SMC)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Somerset, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 2, 2026, 6:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients

NCT04432766
View directory record Official record
Conditions
COVID-19
Interventions
BAT2020
Drug
Lead sponsor
Bio-Thera Solutions
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 2, 2026, 6:45 PM EDT
Suspended Phase 1 Interventional

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

NCT05279300
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Lymphoma
Interventions
CS5001, Rituximab, Gemcitabine, Oxaliplatin, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug · Biological
Lead sponsor
CStone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
East Setauket, New York • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)

NCT05776823
View directory record Official record
Conditions
Opioid Use Disorder, Overdose
Interventions
Pharmacist Narcan Training, BIRT, SMC, Substance Use Counselor Narcan Training
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Co-Use of Opioid Medications and Alcohol Prevention Study

NCT05599672
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use
Interventions
Alcohol-targeted Brief Intervention-Medication Therapy Management, Standard medication counseling
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 2, 2026, 6:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 2, 2026, 6:45 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 2, 2026, 6:45 PM EDT